Eisai Opens Regional Office in Bahrain
JCN Network - Home
JCN Newswire
 Search:    Companies  | Annual Reports  |  CSR  | News Alerts  |  Japanese   
Company
News Sectors
Automotive
Chemicals
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Tech
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
Eisai Opens Regional Office in Bahrain - JCN Newswire
Eisai Opens Regional Office in Bahrain

Tokyo, Oct 16, 2009 - (JCN Newswire) - Eisai Co., Ltd. announced today the opening of a regional office in Bahrain. The new office has been established as a branch of its Asian headquarters Eisai Asia Regional Services Pte. Ltd., in Singapore.

Eisai started doing business with the Middle East in the 1960's. It has since focused on the sale of products imported from Japan and up until now has been using local distributors to deliver these in-house developed pharmaceuticals and other products to patients.

This year Eisai launched Methycobal(R), a treatment for peripheral neuropathy, in Saudi Arabia, the biggest market in the Middle East, and the United Arab Emirates, and from next year it also hopes to receive approval to market other new products.

With this in mind, Eisai has been moving forward with preparations for the opening of the Bahrain Regional Office in order to establish an operational base in the area, as it looks towards full-scale business expansion in the Middle East and North Africa in the future. Eisai will commence operations in the region primarily through working with local distributors, while taking responsibility for marketing and registration of pharmaceutical products.

The Middle East and North Africa has a population of over 400 million, and is currently faced with an increase in lifestyle-related diseases such as obesity and diabetes as well as an aging society. Above all, diabetes is one of the issues affecting the region as it has the highest prevalence rate in the world. Eisai expects to make contributions to patients with diabetic neuropathy in the region through the availability of Methycobal.

Eisai currently operates globally in the United States, Europe and Asia. The Company sees the opening of the Bahrain Regional Office as an opportunity to make its in-house products available continuously as well as to actively introduce licensed products, which match the needs of the Middle East and North Africa, thereby contributing to addressing the needs and increasing the benefits of patients and their families in the region.

Outline of Bahrain Regional Office
Registered Company Name:  Eisai Asia Regional Services Pte. Ltd. 
Dated Established:        June 2009 
Location:                 AL-SEEF, Kingdom of Bahrain 
Director:                 Yasushi Okada 
Scope of Business:        Marketing and registration of 
                          pharmaceutical products


About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit www.eisai.co.jp .



Contact:

PR Department
Eisai Co., Ltd.
+81-3-3817-5120
 

Oct 16, 2009
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary
View more news from these Sectors: Health/Medical


 
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)